Original Katsura branch rice inner mesh
Great content
On February 10, Deyuan Pharmaceutical, a company listed on the Beijing Stock Exchange, issued an announcement that the company produced a batch production of acarbose tablets according to the imitation of 4 types and regarded as the same evaluation. Acarbose tablets are α-glycosidase inhibitors, with a total sales volume of more than 5 billion yuan in 2020 in china's public medical institutions and China's urban physical pharmacies. Up to now, Deyuan Pharmaceutical has 7 diabetic drugs evaluated.
The original company of acarbose tablets is Bayer, Germany, which was first listed in Germany in 1990 and approved in China in 1994. As a α-glycosidase inhibitor, acarbose tablets competitively inhibit the α-glycosidase activity level by binding to the epithelial cells of the small intestinal mucosa, delaying or inhibiting the conversion of amylase into glucose, and achieving the purpose of effectively lowering blood sugar.
According to data from the intranet, in 2020, China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminal acarbose sales totaled more than 5 billion yuan, which is the best-selling oral hypoglycemic drug in China.
At present, the domestic listed acarbose products include acarbose tablets, acarbose capsules, and chewable acarbose tablets. Acarbose tablets are the object of imitation by domestic pharmaceutical companies, and in the past two years, a total of 9 local enterprises have been approved to produce this variety, and there are already 12 manufacturers.
Deyuan Pharmaceutical evaluates drugs through consistency through/deemed identical
Source: MED2.0 China Drug Review Database
As a pharmaceutical manufacturing enterprise focusing on the field of endocrine therapeutic drugs, Deyuan Pharmaceutical has 9 varieties passed/treated as consistency evaluation, of which 7 are diabetes drugs, and 4 varieties such as metformin hydrochloride extended-release tablets, naglilinide tablets, pioglitazone hydrochloride tablets, and pioglitazone metformin tablets are the first to be evaluated.
Data source: Intranet database, company announcements
Note: The Minnei Network China Urban Physical Pharmacy Terminal Competition Pattern Database is an enlarged version of the urban physical pharmacy database covering 297 urban physical pharmacies in prefectures and cities and above (excluding county and rural physical pharmacies) across the country and continuously monitoring all categories. The above sales are calculated based on the average retail price of the product at the terminal.